{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:49:53Z","timestamp":1792590593761,"version":"4.5.0"},"reference-count":31,"publisher":"MyJove Corporation","issue":"232","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/70890","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:20Z","timestamp":1781650820000},"source":"Crossref","is-referenced-by-count":0,"title":["Multifactorial Risk Assessment and Anticoagulation Strategy Optimization for Deep Vein Thrombosis After Major Joint Surgery: A Retrospective Study"],"prefix":"10.3791","author":[{"given":"Gengwu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingguo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/medicina56090416","type":"journal-article","article-title":"An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020","volume":"56","author":"Santana","year":"2020","unstructured":"Santana, D. C. et al. An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020. Medicina. 56 (9), 416 (2020).","journal-title":"Medicina"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.arth.2020.02.030","type":"journal-article","article-title":"Projections and epidemiology of revision hip and knee arthroplasty in the United States to 2030","volume":"35","author":"Schwartz","year":"2020","unstructured":"Schwartz, A. M., Farley, K. X., Guild, G. N., Bradbury, T. L. Projections and epidemiology of revision hip and knee arthroplasty in the United States to 2030. J Arthroplasty. 35 (6), S79\u2013S85 (2020).","journal-title":"J Arthroplasty"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3346\/jkms.2016.31.1.80","type":"journal-article","article-title":"Venous thromboembolism following hip and knee replacement arthroplasty in Korea: a nationwide study based on claims registry","volume":"31","author":"Lee","year":"2016","unstructured":"Lee, S. et al. Venous thromboembolism following hip and knee replacement arthroplasty in Korea: a nationwide study based on claims registry. J Korean Med Sci. 31 (1), 80\u201388 (2016).","journal-title":"J Korean Med Sci"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"e2345883","DOI":"10.1001\/jamanetworkopen.2023.45883","type":"journal-article","article-title":"Venous thromboembolism in total hip and total knee arthroplasty","volume":"6","author":"Simon","year":"2023","unstructured":"Simon, S. J., Patell, R., Zwicker, J. I., Kazi, D. S., Hollenbeck, B. L. Venous thromboembolism in total hip and total knee arthroplasty. JAMA Netw Open. 6 (12), e2345883 (2023).","journal-title":"JAMA Netw Open"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaccao.2022.10.014","type":"journal-article","article-title":"Effectiveness and safety of rivaroxaban and low molecular weight heparin in cancer-associated venous thromboembolism","volume":"5","author":"Coleman","year":"2023","unstructured":"Coleman, C. I. et al. Effectiveness and safety of rivaroxaban and low molecular weight heparin in cancer-associated venous thromboembolism. JACC CardioOncol. 5 (2), 189\u2013200 (2023).","journal-title":"JACC CardioOncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.thromres.2020.12.007","type":"journal-article","article-title":"Thromboprophylaxis for orthopedic surgery: an updated meta-analysis","volume":"199","author":"Haykal","year":"2021","unstructured":"Haykal, T. et al. Thromboprophylaxis for orthopedic surgery: an updated meta-analysis. Thromb Res. 199, 43\u201353 (2021).","journal-title":"Thromb Res"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamasurg.2018.3858","type":"journal-article","article-title":"Association of aspirin with prevention of venous thromboembolism in patients after total knee arthroplasty compared with other anticoagulants","volume":"154","author":"Hood","year":"2019","unstructured":"Hood, B. R. et al. Association of aspirin with prevention of venous thromboembolism in patients after total knee arthroplasty compared with other anticoagulants. JAMA Surg. 154 (1), 65 (2019).","journal-title":"JAMA Surg"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.04.012","type":"journal-article","article-title":"The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty","volume":"155","author":"Chu","year":"2017","unstructured":"Chu, J. N., Maselli, J., Auerbach, A. D., Fang, M. C. The risk of venous thromboembolism with aspirin compared to anticoagulants after hip and knee arthroplasty. Thromb Res. 155, 65\u201371 (2017).","journal-title":"Thromb Res"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00402-015-2208-8","type":"journal-article","article-title":"Risk factors for venous thromboembolism after total hip and total knee arthroplasty: a meta-analysis","volume":"135","author":"Zhang","year":"2015","unstructured":"Zhang, J., Chen, Z., Zheng, J., Breusch, S. J., Tian, J. Risk factors for venous thromboembolism after total hip and total knee arthroplasty: a meta-analysis. Arch Orthop Trauma Surg. 135 (6), 759\u2013772 (2015).","journal-title":"Arch Orthop Trauma Surg"},{"issue":"23 Suppl 1","key":"ref10","first-page":"1-9","type":"journal-article","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","unstructured":"Anderson, F. A., Spencer, F. A. Risk factors for venous thromboembolism. Circulation. 107 (23 Suppl 1), 1-9\u20131-16 (2003).","journal-title":"Circulation"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/imj.16407","type":"journal-article","article-title":"Prevalence of risk factors for venous thromboembolism and aspirin resistance in Australian patients undergoing total hip and knee arthroplasty","volume":"54","author":"van Oosterom","year":"2024","unstructured":"van Oosterom, N., Barras, M., Cottrell, N. Prevalence of risk factors for venous thromboembolism and aspirin resistance in Australian patients undergoing total hip and knee arthroplasty. Intern Med J. 54 (8), 1275\u20131282 (2024).","journal-title":"Intern Med J"},{"issue":"9596","key":"ref12","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","type":"journal-article","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","unstructured":"von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 370 (9596), 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"ref13","volume-title":"Local treatment protocol for rivaroxaban 10 mg tablets (Xarelto\u00ae)\u25bc","year":"2010","unstructured":"NHS Tayside Drug & Therapeutics Committee. Local treatment protocol for rivaroxaban 10 mg tablets (Xarelto\u00ae)\u25bc. At < https:\/\/www.nhstaysideadtc.scot.nhs.uk\/approved\/NMIP\/rivaroxabanprot.pdf> (2010).","type":"book"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/jth.15153","type":"journal-article","article-title":"Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs","volume":"19","author":"Schaefer","year":"2021","unstructured":"Schaefer, J. K. et al. Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. J Thromb Haemost. 19 (1), 212\u2013220 (2021).","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1111\/jth.15048","type":"journal-article","article-title":"Definition of major bleeding: prognostic classification","volume":"18","author":"Franco","year":"2020","unstructured":"Franco, L. et al. Definition of major bleeding: prognostic classification. J Thromb Haemost. 18 (11), 2852\u20132860 (2020).","journal-title":"J Thromb Haemost"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/jamasurg.2014.1841","type":"journal-article","article-title":"Surgical duration and risk of venous thromboembolism","volume":"150","author":"Kim","year":"2015","unstructured":"Kim, J. Y. S. et al. Surgical duration and risk of venous thromboembolism. JAMA Surg. 150 (2), 110 (2015).","journal-title":"JAMA Surg"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1186\/s12891-021-04453-9","type":"journal-article","article-title":"Risk factors for venous thromboembolism in patients with diabetes undergoing joint arthroplasty","volume":"22","author":"Deng","year":"2021","unstructured":"Deng, W. et al. Risk factors for venous thromboembolism in patients with diabetes undergoing joint arthroplasty. BMC Musculoskelet Disord. 22 (1), 608 (2021).","journal-title":"BMC Musculoskelet Disord"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1552893","DOI":"10.3389\/fmed.2025.1552893","type":"journal-article","article-title":"Efficacy and safety of tranexamic acid in reducing hidden blood loss during unilateral total knee arthroplasty: a retrospective study","volume":"12","author":"Liangliang","year":"2025","unstructured":"Liangliang, L., Wei, H., Tao, Z., Pin, P., Lianying, H. Efficacy and safety of tranexamic acid in reducing hidden blood loss during unilateral total knee arthroplasty: a retrospective study. Front Med. 12, 1552893 (2025).","journal-title":"Front Med"},{"issue":"26","key":"ref19","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","type":"journal-article","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","unstructured":"Eriksson, B. I. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 358 (26), 2765\u20132775 (2008).","journal-title":"N Engl J Med"},{"issue":"9632","key":"ref20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","type":"journal-article","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","unstructured":"Kakkar, A. K. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 372 (9632), 31\u201339 (2008).","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.thromres.2014.06.020","type":"journal-article","article-title":"Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis","volume":"134","author":"G\u00f3mez-Outes","year":"2014","unstructured":"G\u00f3mez-Outes, A., Terleira-Fern\u00e1ndez, A. I., Lecumberri, R., Su\u00e1rez-Gea, M. L., Vargas-Castrill\u00f3n, E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 134, 774\u2013782 (2014).","journal-title":"Thromb Res"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","type":"journal-article","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","unstructured":"Lassen, M. R. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 361 (6), 594\u2013604 (2009).","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jor.2022.02.003","type":"journal-article","article-title":"The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis","volume":"30","author":"Xu","year":"2022","unstructured":"Xu, J., Chang, D., Chui, J., Cao, J., Negus, J. The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. J Orthop. 30, 1\u20136 (2022).","journal-title":"J Orthop"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.arth.2018.04.043","type":"journal-article","article-title":"The efficacy of tranexamic acid in total knee arthroplasty: a network meta-analysis","volume":"33","author":"Fillingham","year":"2018","unstructured":"Fillingham, Y. A. et al. The efficacy of tranexamic acid in total knee arthroplasty: a network meta-analysis. J Arthroplasty. 33 (10), 3090\u20133098.e1 (2018).","journal-title":"J Arthroplasty"},{"issue":"9275","key":"ref25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(00)05249-1","type":"journal-article","article-title":"Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials","volume":"358","author":"Eikelboom","year":"2001","unstructured":"Eikelboom, J. W., Quinlan, D. J., Douketis, J. D. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 358 (9275), 9\u201315 (2001).","journal-title":"Lancet"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/ijlh.12665","type":"journal-article","article-title":"Review of D-dimer testing: good, bad, and ugly","volume":"39","author":"Linkins","year":"2017","unstructured":"Linkins, L.-A., Takach Lapner, S. Review of D-dimer testing: good, bad, and ugly. Int J Lab Hematol. 39 (1), 98\u2013103 (2017).","journal-title":"Int J Lab Hematol"},{"issue":"9676","key":"ref27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","type":"journal-article","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","unstructured":"Turpie, A. G. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 373 (9676), 1673\u20131680 (2009).","journal-title":"Lancet"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V110.11.6.6","type":"journal-article","article-title":"Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD1 trial","volume":"110","author":"Eriksson","year":"2007","unstructured":"Eriksson, B. I. et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD1 trial. Blood. 110 (11), 6\u20136 (2007).","journal-title":"Blood"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","type":"journal-article","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","unstructured":"Kubitza, D., Becka, M., Voith, B., Zuehlsdorf, M., Wensing, G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 78 (4), 412\u2013421 (2005).","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/j.1538-7836.2012.04877.x","type":"journal-article","article-title":"Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry","volume":"10","author":"Beyer-Westendorf","year":"2012","unstructured":"Beyer-Westendorf, J. et al. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry. J Thromb Haemost. 10 (10), 2045\u20132052 (2012).","journal-title":"J Thromb Haemost"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","type":"journal-article","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","unstructured":"Falck-Ytter, Y. et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 141 (2), e278S\u2013e325S (2012).","journal-title":"Chest"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/70890\/multifactorial-risk-assessment-anticoagulation-strategy-optimization","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:30:19Z","timestamp":1792589419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/70890\/multifactorial-risk-assessment-anticoagulation-strategy-optimization"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":31,"journal-issue":{"issue":"232","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/70890","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}